In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2515-2524

  Lim, Tze Peng ^a,c   Cai, Yiying ^a   Hong, Yanjun ^b   Chan, Eric Chun Yong ^b   Suranthran, Sasikala ^a,f   Teo, Jocelyn Qi Min ^a   Lee, Winnie Huiling ^a   Tan, Thean Yen ^d   Hsu, Li Yang ^c   Koh, Tse Hsien ^a   Tan, Thuan Tong ^a   Kwa, Andrea Lay Hoon ^a,e  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c National University Hospital System   (Singapore)

^d CHANGI GENERAL HOSPITAL   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; POLYMYXIN B; RIFAMPICIN; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; BACTERIUM ISOLATE; DRUG EFFICACY; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POLYMYXIN B; THIENAMYCINS;

EID: 84931287843     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03639-14     Document Type: Article

References (46)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
2. Tan TY, Hsu LY, Koh TH, Ng LS, Tee NW, Krishnan P, Lin RT, Jureen R. 2008. Antibiotic resistance in Gram-negative bacilli: a Singapore perspective. Ann Acad Med Singapore 37:819-825.
3. Koh TH, Cao D, Shan QY, Bacon A, Hsu LY, Ooi EE. 2013. Acquired carbapenemases in Enterobacteriaceae in Singapore, 1996-2012. Pathology 45:600-603. http://dx.doi.org/10.1097/PAT.0b013e3283650b1e.
4. Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, Koh TH, Network for Antimicrobial Resistance Surveillance (Singapore). 2010. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 54:1173-1178. http://dx.doi.org/10.1128/AAC.01076-09.
5. Pucci MJ, Bush K. 2013. Investigational antimicrobial agents of 2013. Clin Microbiol Rev 26:792-821. http://dx.doi.org/10.1128/CMR.00033-13.
6. Rahal JJ. 2008. The role of carbapenems in initial therapy for serious Gram-negative infections. Crit Care 12(Suppl 4):S5. http://dx.doi.org/10.1186/cc6821.
7. Bratu S, Brooks S, Burney S, Kochar S, Gupta J, Landman D, Quale J. 2007. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 44:972-975. http://dx.doi.org/10.1086/512370.
8. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 165:1430-1435. http://dx.doi.org/10.1001/archinte.165.12.1430.
9. Lolans K, Rice TW, Munoz-Price LS, Quinn JP. 2006. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 50:2941-2945. http://dx.doi.org/10.1128/AAC.00116-06.
10. Villegas MV, Kattan JN, Correa A, Lolans K, Guzman AM, Woodford N, Livermore D, Quinn JP. 2007. Dissemination of Acinetobacter baumannii clones with OXA-23 carbapenemase in Colombian hospitals. Antimicrob Agents Chemother 51:2001-2004. http://dx.doi.org/10.1128/AAC.00226-07.
11. Lomaestro BM, Tobin EH, Shang W, Gootz T. 2006. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 43:e26-e28. http://dx.doi.org/10.1086/505598.
12. Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E, Vitti D, Tsalidou M, Maniatis AN, Tsakris A, Sofianou D. 2009. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother 64:348-352. http://dx.doi.org/10.1093/jac/dkp207.
13. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. 2007. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 51:3026-3029. http://dx.doi.org/10.1128/AAC.00299-07.
14. Hirsch EB, Tam VH. 2010. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65:1119-1125. http://dx.doi.org/10.1093/jac/dkq108.
15. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. 2011. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17:1798-1803. http://dx.doi.org/10.1111/j.1469-0691.2011.03514.x.
16. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56:2108-2113. http://dx.doi.org/10.1128/AAC.06268-11.
17. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2011. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268-281. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x.
18. Lim TP, Suranthran S, Lee W, Tahir N, Cai YY, Koh TH, Tan TY, Hsu LY, Tan TT, Kwa AL. 2012. In vitro activity of piperacillin-tazobactam in combination with various antibiotics against extreme drug-resistant Enterobacteriaceae with reduced susceptibilities to polymyxin B, abstr E-195. Intersci Conf Antimicrob Agents Chemother, 9 to 12 September 2012, San Francisco, CA.
19. Lim TP, Cai YY, Teo J, Suranthran S, Lee W, Koh TH, Tan TY, Hsu LY, Tan TT, Kwa AL. 2013. In vitro pharmacodynamics of tigecycline alone and in combination with meropenem against extreme drug-resistant Klebsiella pneumoniae with decreased susceptibility to polymyxin B in a hollow fiber infection model, abstr E-1158. Intersci Conf Antimicrob Agents Chemother, 10 to 13 September 2013, Denver, CO.
20. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51:3781-3788. http://dx.doi.org/10.1128/AAC.01533-06.
21. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:1298-1304. http://dx.doi.org/10.1086/592577.
22. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. 2006. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 58:1221-1229. http://dx.doi.org/10.1093/jac/dkl403.
23. Tod M, Lortholary O, Seytre D, Semaoun R, Uzzan B, Guillevin L, Casassus P, Petitjean O. 1998. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother 42:849-856.
24. Burgess DS, Summers KK, Hardin TC. 1999. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Clin Ther 21:1882-1889. http://dx.doi.org/10.1016/S0149-2918(00)86736-3.
25. Rebuck JA, Fish DN, Abraham E. 2002. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22:1216-1225. http://dx.doi.org/10.1592/phco.22.15.1216.33484.
26. Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. 2003. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 47:1853-1861. http://dx.doi.org/10.1128/AAC.47.6.1853-1861.2003.
27. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sorgel F. 2007. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenemcilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 51:3304-3310. http://dx.doi.org/10.1128/AAC.01318-06.
28. Zhanel GG, Derkatch S, Laing N, Noreddin AM, Hoban DJ. 2007. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model. J Antimicrob Chemother 59:144-147. http://dx.doi.org/10.1093/jac/dkl433.
29. Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB. 2009. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 34:429-433. http://dx.doi.org/10.1016/j.ijantimicag.2009.07.004.
30. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. 2005. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 49:1337-1339. http://dx.doi.org/10.1128/AAC.49.4.1337-1339.2005.
31. Jaruratanasirikul S, Wongpoowarak W, Kositpantawong N, Aeinlang N, Jullangkoon M. 2012. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia. Int J Antimicrob Agents 40:434-439. http://dx.doi.org/10.1016/j.ijantimicag.2012.07.014.
32. Bulik CC, Nicolau DP. 2011. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55:3002-3004. http://dx.doi.org/10.1128/AAC.01420-10.
33. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26-A, vol 19. National Committee for Clinical Laboratory Standards, Wayne, PA.
34. Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL. 1994. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother 38:1386-1391. http://dx.doi.org/10.1128/AAC.38.6.1386.
35. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15(Suppl A):125-130.
36. D'Argenio DZ, Schumitzky A. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
37. Tam VH, Schilling AN, Nikolaou M. 2005. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 55:699-706. http://dx.doi.org/10.1093/jac/dki086.
38. Koh TH, Cao DY, Chan KS, Wijaya L, Low SB, Lam MS, Ooi EE, Hsu LY. 2012. blaOXA-181-positive Klebsiella pneumoniae, Singapore. Emerg Infect Dis 18:1524-1525. http://dx.doi.org/10.3201/eid1809.111727.
39. Elemam A, Rahimian J, Doymaz M. 2010. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 48:3558-3562. http://dx.doi.org/10.1128/JCM.01106-10.
40. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, Landman D. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 56:128-132. http://dx.doi.org/10.1093/jac/dki175.
41. Tängdén T, Hickman RA, Forsberg P, Lagerback P, Giske CG, Cars O. 2014. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 58:1757-1762. http://dx.doi.org/10.1128/AAC.00741-13.
42. Urban C, Mariano N, Rahal JJ. 2010. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 54:2732-2734. http://dx.doi.org/10.1128/AAC.01768-09.
43. Levin BR, Lipsitch M, Perrot V, Schrag S, Antia R, Simonsen L, Walker NM, Stewart FM. 1997. The population genetics of antibiotic resistance. Clin Infect Dis 24(Suppl 1):S9-S16.
44. Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH. 2012. Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother 67:928-932. http://dx.doi.org/10.1093/jac/dkr560.
45. Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH. 2011. Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother 66:1311-1317. http://dx.doi.org/10.1093/jac/dkr105.
46. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. 2013. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57:5104-5111. http://dx.doi.org/10.1128/AAC.01230-13.